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Abstract
In December 2019, novel cases of pneumonia were reported for the 1st time in Wuhan, Hubei, China. A novel 
virus of the big family of coronavirus (COV) was identified as the pathogen, which causes severe acute respiratory 
syndrome (SARS). The disease is called COV Disease-19 and then SARS-COV 2. The infectious disease has 
spread worldwide with major number of patients in China, Italy, Spain, France, and the USA. On March 11, 2020, the 
WHO declared the outbreak of SARS-CoV-2 a pandemic. Morbidity and mortality of the disease cannot yet estimate 
but have already seen that lethality appears to be particularly higher in older patients. The aim of this article is to 
present a characteristic clinical picture as case report SARS-COV 2 pneumonia and to provide an overview of the 
existing literature.
Introduction
In December 2019, many pneumonia cases 
were reported in China, Wuhan. The source has shown 
Huanan Seafood Market as the origin discovering an 
unexplained pneumonia on December 12, 2019 [1]. 
On January 22, 2020, novel coronavirus (CoV) has 
been declared to be originated from wild bats as part 
of beta-COV who cause severe acute respiratory 
syndrome-associated COV (SARS-CoV). COVs 
are zoonotic pathogens that are present in humans 
and various animals with a wide range of clinical 
features from asymptomatic course to requirement 
of hospitalization in the intensive care unit, causing 
infections in respiratory, gastrointestinal, hepatic, and 
neurologic systems. All CoVs are pleomorphic RNA 
viruses characteristically crown shape with 80–160 nM 
in size and 27–32 kb positive polarity [2], [3], [4], [5]. 
The disease caused by SARS-CoV-2 is called COV 
disease (COVID)-19 which has since spread worldwide 
with major number of patients in China, Italy, Spain, 
France, and the USA. On March 11, 2020, the WHO 
declared the outbreak of SARS-CoV-2 a pandemic. 
Morbidity and mortality of the disease cannot yet 
estimate but have already seen that lethality appears to 
be particularly higher in older patients. In a cohort study 
of 41 hospitalized patients, fever, dry cough, myalgia, 
and fatigue symptoms were reported in most patients, 
and less often, symptoms of expectoration, headache, 
hemoptysis, and diarrhea were also observed [6]. 
Comorbidities such as underlying hypertension, 
diabetes mellitus, and cardiovascular disease, and 
autoimmune diseases were found in about half of these 
patients. Dyspnea, acute respiratory distress syndrome, 
and cardiovascular complications accompanied by 
abnormal thorax computed tomography (CT) compatible 
with pneumonia mean 8 days after the admission. 
X-rays or thorax CT images of the patients revealed 
bilateral multilobar ground-glass opacities (GGOs), with 
peripheral posterior distribution [7], [8]. 
The aim of this article is to present a 
characteristic clinical picture as case report as 
SARS-COV-2 pneumonia and to provide an overview 
of the existing literature.
Case report
A 60-year-old man with a medical history 
of prostatectomy for cancer, osseous metastases, 
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and hormone therapy, presented to the emergency 
department in mid-March after fever, cough, ageusia, 
and anosmia at home for 20 days. He referred myalgias 
and cough at the beginning followed by fevers and said 
that his symptoms persisted despite the medication 
with paracetamol and antibiotics. The patient stated 
that he had shortness of breath in the past 3 days. 
He had had no recent travel outside of the state or 
internationally. On admission, the patient was afebrile 
with a mild non-productive cough. He had limitation in 
exercise tolerance during this acute illness. Admission 
vital signs were heart rate 80 beats/min, blood pressure 
150/90 mmHg, respiratory rate 18, pulse oximetry 
99% on air, and temperature 36.5°C. The results of 
routine laboratory parameters are shown: Leukocytes 
10.78 × 103/mmc, lymphocytes 17.6%, D-DIMERO 
5.246 ng/ml fibrinogen equivalent units, Polymerase 
Chain Reaction (PCR) 1.10 mg/dl, and pro-calcitonin 
0.03 ng/ml. Arterial blood gases (ABGs): pH 7, 450, 
PCO2 35.0 mmHg, PO2 68.0 mmHg, PO2/FiO2 (P/F 
ratio) 324.0 mmHg. PCR testing for other respiratory 
viruses, Mycoplasma pneumoniae and Chlamydia 
pneumoniae, on the throat swab was negative. Nose 
and throat samples for SARS-CoV-2 PCR were obtained 
that returned positive. Examination of the lungs reveals 
murmur reduced and reduce vesicular murmur and 
tactile vocal fremitus bilaterally. He had also bilateral 
scleral injection. After arrival, the patient was placed 
on maximum isolation precautions (negative pressure 
room, with anyone entering the room required to wear 
an N95 respirator, face shield, disposable gown, and 
gloves). A CT chest showed bilaterally multiple patchy 
GGOs and crazy paving is seen. Some of the opacities 
are round and some geographic shaped. Partially, the 
lesions are sharply demarcated against the surrounding 
healthy lung. The left lower lobe and the periphery of 
the lungs are predominantly involved (Figure 1a-i). He 
subsequently worsened because of his SO2 became 
85% despite 12/l/min of oxygen and his P/F ratio was 
inferior to 200 in a new ABG. Hence, he was admitted in 
an intensive care unit for mild respiratory failure. He was 
treated with oxygen therapy using continuous positive 
airway pressure, adjusted following continuous ABG. 
We associated antibiotics such as azithromycin 500 mg 
a day, hydrossicloroquine 400 mg day for the first 48 h, 
and then 200 mg for other 10 days and enoxaparin 
adjusted following patient weight. Darunavir/cobicistat 
800/150 mg a day was avoided because 20 days of 
symptoms onset and tocilizumab was not necessary 
because the patients improved. He was discharged 
15 days after.
Discussion
Novel CoV has been declared to be 
originated from wild bats as part of beta-COV who 
cause SARS-associated COV (SARS-CoV). COVs 
are zoonotic pathogens that are present in humans 
and various animals with a wide range of clinical 
features from asymptomatic course to requirement 
of hospitalization in the intensive care unit, causing 
infections in respiratory, gastrointestinal, hepatic, and 
neurologic systems. Coronaviridae was discovered 
in the 1960s. The name COV originates from the 
Latin word corona, meaning “crown” or “halo,” due to 
its characteristic appearance under two-dimensional 
transmission electron microscopy. COVs have club-
shaped spike peplomers covering their surfaces [9] 
(Figure 2a and b). SARS-CoV, Middle East respiratory 
syndrome (MERS)-CoV, and SARS-CoV-2 belong to 
the Coronaviridae family. This family of viruses contains 
a relatively large single-stranded, positive-sense RNA 
genome of around 27–32 kb. The most important 
potential therapeutic target is the spike (S) glycoprotein, 
which is responsible for the binding of the virus to the 
host cells. It has been reported that the binding of 
the viral S protein to angiotensin-converting enzyme 
(ACE)2 receptors. Increased ACE activity consequently 
results in the elevated levels of angiotensin II. Once 
angiotensin II binds to its receptor, AGTR1A, pulmonary 
vascular permeability is increased [10], [11], [12]. As of 
April 06, 2020, a total of 1,285,257 cases of COVID-19 
occurring in at least 170 countries and territories were 
reported, with approximately 5.4 % of fatality rate 
Figure 1: (a-i) Bilaterally multiple patchy ground-glass opacities and 
crazy paving are seen. Some of the opacities are round and some 
geographic shaped. Partially, the lesions are sharply demarcated 
against the surrounding healthy lung. The left lower lobe and the 
periphery of the lungs are predominantly involved Images 
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Figure 2: (a and b) Electron microscopy image of SARS-CoV-2
a b
  Coco and Leanza. Severe Acute Respiratory Syndrome-coronavirus 2 Interstitial Bilateral Pneumonia
Open Access Maced J Med Sci. 2020 Sep 03; 8(T1):229-232. 231
(70,344/1,285,257) [13]. In a study of 1099 patients in 
China with confirmed COVID-19, the most commonly 
reported symptom was fever (43.8% on initial admission 
and 88.7% during hospitalization) followed by cough 
(67.8%) [14], [15]. Atypical chest and back pain has also 
been reported as presenting symptoms. Chest CT is 
more efficient in detecting pneumonia at the early stages 
of COVID-19. The most common patterns of COVID-19 
on chest CT scans include multiple GGO (56.4%), 
and bilateral patchy shadowing (51.8%), and the other 
patterns consist of local patchy shadowing (28.1%) 
and interstitial abnormalities (4.4%) [6], [16], [17]. 
Today, there is no vaccine or effective treatment to 
prevent COVID-19 infection. Early diagnosis, reporting, 
isolation, and basic measures such as hand washing, 
using disinfectant solutions, avoiding contact with 
patients, and supportive treatments are the most helpful. 
There are publications demonstrating that remdesivir 
has a strong antiviral activity in epithelial cell cultures 
against SARS-CoV, MERS-CoV, and related zoonotic 
bat CoV [18], [19]. As part of MERS cure, a randomized 
control trial (MIRACLE Trial 2016) from South Korea 
determines that the combination of lopinavir/ritonavir 
(anti-HIV drugs), pegylated interferon, and ribavirin 
provided a successful viral clearance [16]. Chloroquine, 
typically used in the context of malarial or autoimmune 
disease, has also shown promising results [20], [21]. 
Tocilizumab is a humanized monoclonal antibody 
against interleukin-6 receptor (Ab), commonly used as 
an immunosuppressive in the treatment of rheumatoid 
arthritis and systemic juvenile idiopathic arthritis seems 
to be successful [22], [23]. The duration between onset 
of symptoms and isolation is about 6 days, and it is 
expected that each 1 day reduction in this period will 
decrease the size of peak population by 72–84% and 
cumulative infected cases and deaths by 68–80%. It is 
estimated that with the effects of integrated interventions 
such as promoting the use of face masks and reduced 
traveling, each 10% reduction in transmission rate, the 
size of peak population will decrease by 20–47%, and 
cumulative infected cases and deaths will decrease by 
23–49% [24].
Conclusions
SARS-CoV-2 is the COV responsible for the 
COVID-19 pandemic of 2020. The mean incubation time 
is 5.1 days (95% confidence interval [CI]: 4.5–5.8 days), 
with 97.5% of those who develop symptoms doing so 
within 11.5 days (95% CI: 8.2–15.6 days). Symptoms 
may vary from mild to severe. Those most affected by 
COVID-19 are those of advanced age and those with 
pre-existing chronic medical conditions. Mortality rates 
are currently unknown: From 0.25% to 10%. Treatment 
options are limited. Supportive care is the best choice. 
Ongoing studies are evaluating the efficacy of remdesivir, 
chloroquine, hydroxychloroquine, tocilizumab, lopinavir, 
and ritonavir. At present, no vaccine is available but 
there are progresses to developing a vaccine over the 
coming year.
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